Clinical trials
IrAE clinical trials
Below are recruiting irae clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03989323Recruiting
Register to track cancer immune therapy and side effects
This study sets up a real-world patient database to follow people starting cancer immunotherapy and record immune-related side effects. You may help doctors better understand who gets these side effects and how they change over time.
BronAges 18 years+ - NCT06337695RecruitingPhase 2/Phase 3
Preventing immunotherapy-related diarrhea in advanced cancer
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
Calgary, AlbertaAges 18 years+ - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07174453RecruitingPhase 3
Comparing side effects of different doses of immunotherapy
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Westwood, KansasAges 18 years+ - NCT05813418Recruiting
Finding blood and other clues for immune side effects
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
Amiens, PicardieAges 18 years+ - NCT07381634RecruitingPhase 2
Testing ondansetron to reduce immunotherapy side effects in liver cancer
This study tests whether adding ondansetron (a common anti-nausea drug) can reduce side effects from immunotherapy in people with liver cancer. If you are starting a specific combination treatment for liver cancer, you may be eligible.
Wenzhou, ZhejiangAges 18–80 - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT05628701Recruiting
Testing two UC surgery reconstructions after colectomy
This trial compares two ways of reconnecting the bowel after subtotal colectomy and ileostomy in people with ulcerative colitis (UC). It may help determine which surgical option works best when the rectum is calm enough to manage with topical mesalazine alone.
GothenburgAges 18–60 - NCT06461780Recruiting
Needs and Quality of Life in Advanced Cancer on Immunotherapy
This study looks at the physical and emotional needs of people with advanced cancer who are receiving immunotherapy. It aims to understand how these needs affect quality of life.
TaipeiAges 18 years+ - NCT04968808Recruiting
Find best timing for stent procedure in NSTEMI with multiple vessel disease
This trial compares when to do a stent procedure (PCI) in people with NSTEMI who have disease in more than one coronary artery (non-IRA). It may help doctors choose the safest and most effective timing for treatment to improve outcomes.
GwangjuAges 19 years+ - NCT07237594RecruitingPhase 1
IL-17 blocker to prevent immunotherapy side effects
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
Durham, North CarolinaAges 18 years+
Hear when a new IrAE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for irae?
- Yes. Clin2 currently lists 11 recruiting irae studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a irae trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a irae trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.